NMPA includes new drug listing applications for zanubrutinib and Tirelli Pearl resistance in priority review

announced yesterday (November 15) that the NationalDrug(http://Regulatory Authority (NMPA) Drug Review Center (CDE) will use the Bruton's tyrosine kinase (BTK) inhibitor zanububinib for the treatment of relapse/difficult treatmentnew drug(http:// of sexual lycytoma (MCL)marketapplications and new drug listing applications for anti-PD-1 antibody Terrei bezomono-resistant for the treatment of recurrent/incurable classic Hodgkin lymphoma (R/R cHL) were included in the priority reviewAbout Zanubrutinib and Tirelli Pearl single anti-
Zanubrutinib and Tirelli Pearl single anti-research and development by Baiji Shenzhou's research center in Beijing, ChinaAt present, Baiji Shenzhou is carrying out the clinical development of zanubrutinib as a single drug and combination of drugs with other therapies to treat a wide range of hematologic malignancies, as well as the clinical development of a range of solid tumors and blood tumors treated with terrei Pearl monoantigen as a single drug and combination therapyzanubrutinibZanubrutinib (BGB-3111), a small molecule inhibitor of Bruton's tyrosine kinase (BTK), is currently undergoing a wide range of key clinicaltrials around the world and in China
(http://program for the treatment of multiple lymphomas as a single drug and in combination with other therapiesZanubrutinib's new drug marketing application (NDA) for the treatment of R/R set cell lymphoma (MCL) and R/R chronic lymphocytic leukemia (CLL) or small lymphocytic lymphocyte (SLL) was accepted by NMPA in August and October this year, respectivelyabout the Delli-Bead-
-Tyreli-Single Resistance (BGB-A317), a human-derived monoclonal antibody in the study, belongs to a class called immunocheckpoint inhibitors of the tumor immuno
drug (http:// 's application for a new drug for the treatment of recurrent/incurable classic Hodgkin's lymphoma (R/R cHL) patients was accepted by NMPA in August this year